Table 1 Pooled cohort demographic and clinical characteristics.
Pooled cohort | 1st Validation (JAMA oncology 2016) | 2nd Validation (European urology 2018) | 3rd Validation/utility study (PCAN 2020) | |
|---|---|---|---|---|
Total patient N | 1212 | 519 | 503 | 190a |
Age median, IQR | 63 (58, 69) | 64 (58, 68) | 64 (59, 69) | 63 (58, 69) |
PSA median, IQR | 5.2 (4.3, 6.6) | 5.1 (4.3, 6.4) | 5.4 (4.4, 6.7) | 5.2 (4.4, 6.7) |
Family History | ||||
Yes | 223 (18.4%) | 117 (22.5%) | 72 (14.3%) | 34 (17.9%) |
No | 987 (81.4%) | 402 (77.5%) | 431 (85.7%) | 154 (81.1%) |
NA | 2 (0.2%) | 0 (0%) | 0 (0%) | 2 (1%) |
Ethnicity | ||||
African American | 204 (16.8%) | 87 (16.8%) | 71 (14.1%) | 46 (24.2%) |
Asian/Pacific Islander | 37 (3.1%) | 13 (2.5%) | 18 (3.6%) | 6 (3.2%) |
Caucasian | 854 (70.5%) | 377 (72.6%) | 350 (69.6%) | 127 (66.8%) |
Other | 96 (7.9%) | 35 (6.8%) | 52 (10.4%) | 9 (4.8%) |
NA | 21 1.7(%) | 7 (1.3%) | 12 (2.4%) | 2 (1.1%) |
DRE | ||||
Nonsuspicious | 888 (73%) | 352 (67.8%) | 379 (75.3%) | 157 (82.6%) |
Suspicious | 155 (13%) | 77 (14.8%) | 63 (12.5%) | 15 (7.9%) |
NA | 169 (14%) | 90 (17.3%) | 61 (12.1%) | 18 (9.5%) |
Grade Group | ||||
Benign | 585 (48.3%) | 268 (51.6%) | 234 (46.5%) | 83 (43.7%) |
GG 1 (GS3 + 3) | 261 (21.5%) | 103 (19.8%) | 111 (22.1%) | 47 (24.7%) |
GG 2 (GS3 + 4) | 198 (16.3%) | 84 (16.2%) | 86 (17.1%) | 28 (14.7%) |
GG 3 (GS4 + 3) | 84 (6.9%) | 36 (6.9%) | 26 (5.2%) | 22 (11.6%) |
GG 4 (GS8) | 39 (3.2%) | 11 (2.1%) | 26 (5.2%) | 2 (1.1%) |
GG 5 (> GS8) | 45 (3.7%) | 17 (3.3%) | 20 (4.0%) | 8 (4.2%) |
